NZ592928A - Method for treating parkinson' s disease using filamentous bacteriophage - Google Patents
Method for treating parkinson' s disease using filamentous bacteriophageInfo
- Publication number
- NZ592928A NZ592928A NZ592928A NZ59292809A NZ592928A NZ 592928 A NZ592928 A NZ 592928A NZ 592928 A NZ592928 A NZ 592928A NZ 59292809 A NZ59292809 A NZ 59292809A NZ 592928 A NZ592928 A NZ 592928A
- Authority
- NZ
- New Zealand
- Prior art keywords
- disease
- filamentous bacteriophage
- treating parkinson
- antibody
- bacteriophage
- Prior art date
Links
- 241000724791 Filamentous phage Species 0.000 title abstract 2
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 2
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 2
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 241001515965 unidentified phage Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11744608P | 2008-11-24 | 2008-11-24 | |
| PCT/US2009/065659 WO2010060073A2 (en) | 2008-11-24 | 2009-11-24 | Method for treating parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ592928A true NZ592928A (en) | 2012-12-21 |
Family
ID=41572327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ592928A NZ592928A (en) | 2008-11-24 | 2009-11-24 | Method for treating parkinson' s disease using filamentous bacteriophage |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110286970A1 (enExample) |
| EP (2) | EP2478911A1 (enExample) |
| JP (1) | JP2012509672A (enExample) |
| KR (1) | KR20110091778A (enExample) |
| CN (1) | CN102223887B (enExample) |
| AU (1) | AU2009316326A1 (enExample) |
| BR (1) | BRPI0921557A2 (enExample) |
| CA (1) | CA2744339A1 (enExample) |
| CO (1) | CO6390112A2 (enExample) |
| IL (1) | IL213120A0 (enExample) |
| MX (1) | MX2011005430A (enExample) |
| NZ (1) | NZ592928A (enExample) |
| RU (1) | RU2011125971A (enExample) |
| SG (1) | SG171791A1 (enExample) |
| WO (1) | WO2010060073A2 (enExample) |
| ZA (1) | ZA201104701B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2102239T3 (da) * | 2006-11-30 | 2012-05-29 | Res Dev Foundation | Forbedrede immunoglobulin-biblioteker |
| US20110182948A1 (en) * | 2008-05-22 | 2011-07-28 | Beka Solomon | Method for treating disease characterized by plaque |
| BR112013023040A2 (pt) | 2011-03-11 | 2018-10-23 | Univ Ramot | bacteriófago filamentoso, composição farmacêutica, e, métodos para reduzir a formação de fibrilas de proteína tau ou para desagregar fibrilas pré-formadas de proteína tau em um paciente, e para tratar uma tauopatia degenerativa. |
| EP2736522A1 (en) | 2011-07-27 | 2014-06-04 | Neurophage Pharmaceuticals, Inc. | Process for the production of filamentous bacteriophage |
| US9493515B2 (en) | 2011-11-29 | 2016-11-15 | Proclara Biosciences, Inc. | Bacteriophage gene 3 protein compositions and use as amyloid binding agents |
| EA033666B1 (ru) | 2012-10-02 | 2019-11-14 | Proclara Biosciences Inc | Амилоидсвязывающие белки и их применение |
| JP2016526044A (ja) | 2013-05-28 | 2016-09-01 | ニューロファージ ファーマシューティカルズ， インコーポレイテッド | 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド |
| KR20170085132A (ko) | 2014-12-03 | 2017-07-21 | 프로클라라 바이오사이언시즈, 인크. | 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003509020A (ja) * | 1999-09-03 | 2003-03-11 | ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド | プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法 |
| WO2002042321A2 (en) * | 2000-11-24 | 2002-05-30 | Isis Innovation Limited | Mixed fibrils |
| IL163812A0 (en) * | 2002-03-05 | 2005-12-18 | Univ Ramot | Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein |
| GB0305918D0 (en) * | 2003-03-14 | 2003-04-23 | Glaxo Group Ltd | Novel compounds |
| FR2855178B1 (fr) * | 2003-05-20 | 2005-08-05 | Centre Nat Rech Scient | Peptides modulateurs de l'activite du facteur de transcription engrailed |
| CA2593846A1 (en) * | 2005-01-14 | 2006-08-10 | The Regents Of The University Of California | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders |
| JP5096169B2 (ja) * | 2005-02-01 | 2012-12-12 | ラモット・アット・テルアビブ・ユニバーシティ | アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法 |
| MX2008010612A (es) * | 2006-02-15 | 2009-03-20 | Ramot At Tel Aviv University | Bacteriofago filamentoso que exhibe proteina a como aglutinante de anticuerpos e inmunocomplejos para el suministro hacia el cerebro. |
| US20090324554A1 (en) * | 2006-07-21 | 2009-12-31 | Ramot At Tel Aviv University Ltd. | Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar or aggregates |
| US20110182948A1 (en) * | 2008-05-22 | 2011-07-28 | Beka Solomon | Method for treating disease characterized by plaque |
-
2009
- 2009-11-24 AU AU2009316326A patent/AU2009316326A1/en not_active Abandoned
- 2009-11-24 EP EP12151176A patent/EP2478911A1/en not_active Withdrawn
- 2009-11-24 SG SG2011037066A patent/SG171791A1/en unknown
- 2009-11-24 NZ NZ592928A patent/NZ592928A/xx not_active IP Right Cessation
- 2009-11-24 WO PCT/US2009/065659 patent/WO2010060073A2/en not_active Ceased
- 2009-11-24 JP JP2011537703A patent/JP2012509672A/ja active Pending
- 2009-11-24 KR KR1020117014511A patent/KR20110091778A/ko not_active Withdrawn
- 2009-11-24 BR BRPI0921557A patent/BRPI0921557A2/pt not_active IP Right Cessation
- 2009-11-24 CA CA2744339A patent/CA2744339A1/en active Pending
- 2009-11-24 EP EP09775018A patent/EP2358377A2/en not_active Withdrawn
- 2009-11-24 US US13/130,894 patent/US20110286970A1/en not_active Abandoned
- 2009-11-24 MX MX2011005430A patent/MX2011005430A/es not_active Application Discontinuation
- 2009-11-24 RU RU2011125971/15A patent/RU2011125971A/ru not_active Application Discontinuation
- 2009-11-24 CN CN2009801467441A patent/CN102223887B/zh not_active Expired - Fee Related
-
2011
- 2011-05-24 IL IL213120A patent/IL213120A0/en unknown
- 2011-06-23 CO CO11078816A patent/CO6390112A2/es not_active Application Discontinuation
- 2011-06-24 ZA ZA2011/04701A patent/ZA201104701B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009316326A1 (en) | 2010-05-27 |
| MX2011005430A (es) | 2011-10-28 |
| CO6390112A2 (es) | 2012-02-29 |
| ZA201104701B (en) | 2012-09-26 |
| HK1162964A1 (en) | 2012-09-07 |
| SG171791A1 (en) | 2011-07-28 |
| EP2478911A1 (en) | 2012-07-25 |
| JP2012509672A (ja) | 2012-04-26 |
| US20110286970A1 (en) | 2011-11-24 |
| IL213120A0 (en) | 2011-07-31 |
| CN102223887A (zh) | 2011-10-19 |
| EP2358377A2 (en) | 2011-08-24 |
| KR20110091778A (ko) | 2011-08-12 |
| WO2010060073A2 (en) | 2010-05-27 |
| WO2010060073A3 (en) | 2010-09-02 |
| CA2744339A1 (en) | 2010-05-27 |
| BRPI0921557A2 (pt) | 2019-09-24 |
| CN102223887B (zh) | 2013-11-06 |
| RU2011125971A (ru) | 2012-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ703668A (en) | Complexes of il-15 and il-15ralpha and uses thereof | |
| EP4434550A3 (en) | Human antibody drug conjugates against tissue culture | |
| EA201070463A1 (ru) | Комбинированная терапия с использованием конъюгатов антитело-лекарственное средство | |
| MY161844A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| MX2009005189A (es) | Anticuerpos humanos monoclonales para btla y metodos de uso. | |
| NZ599971A (en) | Monoclonal antibodies to progastrin and their uses | |
| EA031209B9 (ru) | Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения | |
| PH12018500641A1 (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| WO2010054265A3 (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 | |
| SG158112A1 (en) | Hepatocyte growth factor (hgf) binding proteins | |
| NZ595574A (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use | |
| MX2010005830A (es) | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. | |
| WO2008013863A3 (en) | Generation of adipose tissue and adipocytes | |
| MY179851A (en) | Anti-prlr antibodies and uses thereof | |
| GB2496799A (en) | A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders | |
| GB2434157A (en) | Platelets from stem cells | |
| EP3778917A3 (en) | Multispecific antibodies, antibody analogs, compositions, and methods | |
| NZ603191A (en) | Methods for the treatment of il-1b related conditions | |
| NZ600079A (en) | A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma | |
| NZ599315A (en) | Antibody therapeutics with local activity in the digestive tract | |
| WO2010060073A3 (en) | Method for treating parkinson' s disease using filamentous bacteriophage | |
| NZ578065A (en) | Methods for treating psoriasis with an antibody which binds to an epitope | |
| EP2046385A4 (en) | COMPOSITION FOR MODULATING THE EXPRESSION OF CELL ADHESION MOLECULES | |
| MX359125B (es) | Método para fabricar una composición que comprende un anestésico local, un heparinoide y un regulador de ph. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 24 NOV 2016 BY DENNEMEYER SA Effective date: 20131017 |
|
| LAPS | Patent lapsed |